VANCOUVER, Oct. 25 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPI - News; TSX:ANP - News) today filed a Form 6-K (the "Form 6-K") with the U.S. Securities and Exchange Commission ("SEC"), which contains its financial statements for the years ended December 31, 2005 and 2004 and the fifteen months ended December 31, 2003 and as of December 31, 2005 and 2004, and its financial statements for the six months ended June 30, 2006 and 2005 (together, the "Angiotech Statements"). The Form 6-K was filed in conjunction with Angiotech's filing today of a preliminary short form prospectus (the "Preliminary Prospectus") with the British Columbia Securities Commission and a Registration Statement (the "Registration Statement") with the SEC to register the exchange of its previously issued 7.75% Senior Subordinated Notes due April 1, 2014 for new 7.75% Senior Subordinated Notes due April 1, 2014. The notes to be issued to holders that accept the exchange offer are identical to the previously issued notes in all material respects, except that the new notes will be registered under the U.S. Securities Act of 1933.
